Carregant...
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
Safinamide (SAF) is a new drug developed for the treatment of Parkinson’s disease (PD). It is a benzylamino derivative with multiple mechanisms of action and antiparkinsonian, anticonvulsant, and neuroprotective properties. SAF inhibits monoamine oxidase B and dopamine reuptake and glutamate release...
Guardat en:
| Publicat a: | Drug Des Devel Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751980/ https://ncbi.nlm.nih.gov/pubmed/26917951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S77749 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|